Good morning. I'm Nello Mainolfi, President and CEO of Kymera Therapeutics, and I will act as Chairperson of this meeting. I'm pleased to welcome you to the Kymera Therapeutics 2024 Annual Meeting of Shareholders. Before I call the meeting to order, I would like to introduce you to the members of our board and our executive team who are with us here today. The members of the board with us here today are Mr. Jeffrey Albers, Dr. Felix Baker, Dr. Bruce Booth, Dr. Pamela Esposito, Dr. Joanna Horobin, Dr. Gorjan Hrustanovic, Dr. John Maraganore, Ms. Leigh Morgan, Ms. Elena Ridloff, Dr. Victor Sandor. The other executive officers of the corporation with us today are Dr. Jeremy Chadwick, our Chief Operating Officer; Ms. Ellen Chiniara, our Chief Legal Officer and Corporate Secretary; Dr. Jared Gollob, our Chief Medical Officer; Mr. Bruce Jacobs, our Chief Financial Officer.
I would like also to introduce you to Brendan McCorry, of Ernst & Young, the corporation's independent registered public accounting firm. The meeting will now officially come to order. We propose to proceed with the form of business of the meeting as set forth in the corporation's 2024 Notice of Annual Meeting and Proxy Statement. The meeting will be conducted, and questions will be considered in the manner outlined in the rules of conduct available on the virtual meeting website. Will the Secretary please report at this time with respect to the mailing of the notice of the meeting and the shareholders' list?
I have at this meeting a complete list of the shareholders of record of the corporation at the close of business on April 19, 2024, the record date for this meeting, which is and will be available for examination of any shareholder on the virtual meeting website throughout this meeting. I also have with me an affidavit certifying that commencing on April 24, 2024, a notice of internet availability of proxy materials was deposited in the United States Mail to all shareholders of record as of April 19, 2024. The notice provided that shareholders could access and review the corporation's proxy materials, including the proxy card, proxy statement, notice of meeting, and the 2023 Annual Report, or alternatively request a print copy of the proxy materials.
At this time, I'd like to introduce Lou Larson, who's been appointed as the independent inspector of elections at this meeting. Mr. Larson has taken and subscribed the customary oath of office to execute his duties with strict impartiality, which will be filed with the records of the meeting. His function is to decide upon the qualifications of voters, accept their votes, and when balloting on the matter is completed, to tally the final vote. Will the Secretary please report at this time with respect to the existence of a quorum?
I have been informed by the inspector of elections that proxies have been received for 57,662,995 of the 61,358,262 shares of common stock outstanding on the record date, which represents approximately 93.97% of the total number of shares entitled to vote at this meeting. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting.
We will now proceed with the form of business of the meeting. The following proposals are to be considered by our shareholders at this meeting. Proposal one is the election of Pamela Esposito, Gorjan Hrustanovic, and Victor Sandor as Class I Director to serve on the Board of Directors until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified, or until his or her earlier death, resignation, or removal. The Board recommends voting for the Class I Director nominees. Proposal two is to approve a non-binding advisory on a non-binding advisory basis: the compensation of the corporation's named executive officers, as disclosed in the Proxy Statement. The Board recommends a vote for the approval on a non-binding advisory basis of the compensation of the corporation's named executive officers, as disclosed in the Proxy Statement.
Proposal three is to ratify the appointment of Ernst & Young as the corporation's independent registered public accounting firm for the fiscal year ending December 31, 2024. The board recommends a vote for the ratification of the appointment of Ernst & Young as the corporation's independent registered public accounting firm for the fiscal year ending December 31, 2024. Proposal four is to approve an amendment to the Kymera Therapeutics 2020 Stock Option and Incentive Plan. The board recommends voting for the amendment. That was the final proposal for today's meeting. Ms. Ellen Chiniara, Mr. Bruce Jacobs, and I were designated as proxies by certain shareholders. Such shares represented by proxies will be voted in accordance with the instructions given. If no instructions were given, such shares will be voted in accordance with the board's recommendations. The Secretary will now describe the voting procedures.
The time is now 8:35 A.M. Eastern Time on Tuesday, June 18, 2024, and the polls are now open for voting on each of the proposals described by the Chairperson. Voting is by proxy and virtual written ballot. You do not need to vote again if you have already voted your proxy by telephone, by mail, or by internet. Will Mr. Jacobs please advise if we have any questions?
We have no questions.
If anyone attending the meeting, whether or not you have already submitted a proxy, wants to complete the ballot virtually, please follow the instructions on the online portal. The time is now 8:36 P.M. Eastern Time, and the polls are now closed for voting on each of the matters presented.
May we have the results of the voting?
The report of the inspector of elections covering the proposals presented at this meeting is as follows: The proposal to elect Pamela Esposito, Gorjan Hrustanovic, and Victor Sandor as Class I Directors of the corporation is carried. The proposal to approve on a non-binding advisory basis, the compensation of the corporation's named executive officers, as described in the proxy statement, is carried. The proposal to ratify the appointment of Ernst & Young as the independent registered public accounting firm of the corporation for the year ending 2024 is carried. The proposal to approve an amendment to the Kymera Therapeutics Stock Option and Incentive Plan is carried.
There being no other business to properly come before this meeting, this meeting is now adjourned. Thank you for attending the corporation's 2024 Annual Meeting of Shareholders.